TOLEROGENIC POPULATIONS OF DENDRITIC CELLS
    10.
    发明申请
    TOLEROGENIC POPULATIONS OF DENDRITIC CELLS 有权
    致敏细胞的耐受性人群

    公开(公告)号:US20100080816A1

    公开(公告)日:2010-04-01

    申请号:US12566454

    申请日:2009-09-24

    IPC分类号: A61K39/00 C12N5/071 A61P37/02

    摘要: Tolerogenic populations of dendritic cells are provided, where the dendritic cells are characterized by expression of select tissue-specific homing receptors including the chemokine receptors CCR9; or CMKLR1; or the integrin CD103. The dendritic cells may be conventional/myeloid or plasmacytoid dendritic cells. The cells may be isolated from lymphoid tissue, from blood, or from in vitro culture, e.g. bone marrow culture, etc. Methods are provided for their identification, isolation and targeting in immunotherapeutic interventions in suppressing inflammatory disorders including autoimmunity, transplantation responses and allergic diseases. In some embodiments dendritic cell populations are fixed to render them immunosuppressive, thus allowing the cells to be typed and banked for future use.

    摘要翻译: 提供树突状细胞的耐受性种群,其中树突细胞的特征在于选择性组织特异性归巢受体包括趋化因子受体CCR9的表达; 或CMKLR1; 或整合素CD103。 树突状细胞可以是常规/骨髓或浆细胞样树突状细胞。 细胞可以从淋巴组织,血液或体外培养中分离,例如, 骨髓培养等。提供了在免疫治疗干预中鉴别,分离和靶向抑制包括自身免疫,移植反应和过敏性疾病的炎性疾病的方法。 在一些实施方案中,树突状细胞群被固定以使其免疫抑制,从而允许细胞被分型和分组以备将来使用。